InMed Pharmaceuticals Inc (INM)

[lesgetrich]

Does InMed develop drugs or make drugs for other companies? What do they want to do????

There's no reason they can't do both. However, their main focus is still on drug development. In the meantime, if they can bring in some revenue from biosynthesis and/or bioinformatics all the better.

Why do they continue to spend money on this stuff?

The same reason any other company spends money, to make more money. Both these technologies are unique to Inmed and will eventually prove to be very profitable. The only question is how soon.

Teewinot has a Patented bio synthesis process for cannabinoids. Nemus chose them to manufacture their candidates.

So you have competition that has protected their IP.

InMed is also protecting their IP. From InMed's recent prospectus...

InMed Prospectus 9-01-2017

InMed has been approached by another company with an
alternative in vitro production approach, but InMed has elected to pursue its own proprietary in vivo approach. On June 1, 2016, InMed filed a provisional patent application (USPTO No. 62/344,248) covering its inventions in the in vivo enzymatic biosynthesis of cannabinoids.

Teewinot may have been that other company. They appear to use a chemical process that may or may not produce cannabinoids that are bioequivalent to the naturally-occurring products like cannabinoids produced by Biosynthesis. Bioequivalence is very difficult to achieve using a chemical synthesis process. It's also likely that biosynthesis is also simpler, faster, and less costly than chemical synthesis.

Nemus may have chosen Teewinot simply because their product was already available while InMed has not yet set up a production facility or begun marketing.

FOCUS ON THE EB DRUG THE PUMPS MAKE ME SICK

The so-called "pumps" are nothing more than legitimate advertising and branding that is normal for most public companies. No one is hyping the share price or making claims of quick profits as is the case with "pump and dump" schemes. It will take several years before the drugs that Inmed is developing hit the market. Without some publicity in the meantime, the stock price would slowly drift down for lack of new buyers. Investors should be happy that the company is trying to keep itself in the news and make more people aware of its potential. JMO